Barclays raised the firm’s price target on Elevance Health (ELV) to $408 from $393 and keeps an Overweight rating on the shares post the Q1 report. The firm sys its analysis supports strengthening reserves and a “conservative” earnings outlook for Elevance.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health: Strong Earnings Momentum and Attractive Valuation Support Buy Rating and $400 Target
- Elevance Health price target raised to $364 from $357 at Leerink
- Elevance Health price target raised to $331 from $317 at Baird
- AI Models Turn More Positive on Elevance Health After Guidance Boost
- Elevance Health Earnings Call Highlights Growth, Key Risks